Guard Therapeutics

Guard Therapeutics Receives Conditional Approval for Continued Listing on Nasdaq First North Growth Market and Publishes Company Description

Neutral

Sammanfattning

Guard Therapeutics har erhållit villkorat godkännande från Nasdaq för fortsatt notering på First North Growth Market, vilket är avgörande för det planerade omvända förvärvet av Disruptive Pharma. Bolaget har även publicerat en bolagsbeskrivning.

Analys

Det villkorade godkännandet för fortsatt notering är en kritisk milstolpe som avvärjer den tidigare hotande avnoteringen för Guard Therapeutics. Detta möjliggör det omvända förvärvet av Disruptive Pharma, vilket innebär en fundamental förändring av bolagets verksamhet och inriktning. Befintliga aktieägare kommer att äga cirka 45% av det sammanslagna bolaget, vilket medför en betydande utspädning. Godkännandet är dock villkorat av att transaktionen slutförs och att sedvanliga krav uppfylls.
Se relaterad nyhet

Nyckeltal

Ägarandel befintliga aktieägare efter transaktion
ca 45%
Ägarandel säljare av Disruptive Pharma efter transaktion
ca 55%

Insikter

  • • Nyheten bekräftar att bolaget har en väg framåt efter den tidigare hotande avnoteringen.
  • • Det omvända förvärvet innebär en fundamental förändring av bolagets affärsmodell och inriktning.
  • • Fortsatt notering är villkorad av att transaktionen slutförs och att standardkrav uppfylls.
  • • Utspädningen är en konsekvens av den strategiska lösningen för att säkra bolagets framtid.

Guard Therapeutics International AB (publ) ("Guard Therapeutics" or the "Company") has today received conditional approval from Nasdaq Stockholm ("Nasdaq") for the continued listing of the Company's shares on Nasdaq First North Growth Market. The application for continued listing was submitted on 11 June 2026 as part of the implementation of the previously announced planned reverse takeover of Disruptive Pharma Holding AB (publ). The Company is also today publishing a company description.

Guard Therapeutics International AB (publ) ("Guard Therapeutics" or the "Company") has today received conditional approval from Nasdaq Stockholm ("Nasdaq") for the continued listing of the Company's shares on Nasdaq First North Growth Market. The application for continued listing was submitted on 11 June 2026 as part of the implementation of the previously announced planned reverse takeover of Disruptive Pharma Holding AB (publ). The Company is also today publishing a company description.

BackgroundOn 10 June 2026, Guard Therapeutics entered into a conditional agreement to acquire shares in Disruptive Pharma Holding AB (publ) ("Disruptive Pharma") (the "Transaction"). Completion of the Transaction is, among other things, conditional upon the Company obtaining approval for continued listing on Nasdaq First North Growth Market.

The acquisition is intended to be effected through an issue in kind, whereby the Company will issue new shares (the "Consideration Shares") to the sellers in exchange for non-cash consideration consisting of shares in Disruptive Pharma. Assuming that the Transaction comprises all shares in Disruptive Pharma, the sellers will, following completion of the Transaction, hold approximately 55 percent of the shares in the Company, while Guard Therapeutics existing shareholders will hold approximately 45 percent.

Following completion of the Transaction, Disruptive Pharma will become a subsidiary of Guard Therapeutics. In connection therewith, Guard Therapeutics intends to change its corporate name to Disruptive Pharma AB ("New Disruptive Pharma"), and Disruptive Pharma's business will constitute the Company's principal business. Consequently, the Transaction constitutes a so-called reverse takeover.

In light of the fundamental change in the Company's business that the Transaction entails, Guard Therapeutics submitted an application to Nasdaq Stockholm on 11 June 2026 for approval of the continued listing of the Company's shares in connection with the new business.

Conditional Approval for Continued Listing on Nasdaq First North Growth MarketGuard Therapeutics has today received conditional approval from Nasdaq for the continued listing of the Company's shares on Nasdaq First North Growth Market. The approval is subject to customary conditions, including that the Company publishes a company description that is substantially unchanged from the version submitted to Nasdaq in connection with the review process, completes the Transaction, continues to satisfy the shareholder distribution requirement in accordance with the Nasdaq First North Growth Market Rulebook (the "Rulebook"), and updates its website in accordance with the Rulebook.

Company DescriptionThe Company is today publishing the company description that formed the basis for Nasdaq's decision to approve the continued listing of the Company's shares. The company description is available in Swedish only on the Company's website: Omvänt förvärv 2026 - Guard Therapeutics.

For further information regarding the Transaction, please refer to the Company Description and the Company's press releases dated 10 June 2026 concerning the conditional agreement relating to the reverse takeover of Disruptive Pharma and the notice convening the extraordinary general meeting.

For further information, please contact:

Tobias Agervald, CEOTelephone: +46 8 670 65 51E-mail: info@guardtherapeutics.com

About Guard Therapeutics

Guard Therapeutics is a Swedish biotechnology company developing new therapies based on the endogenous protein alpha-1 microglobulin. The company is listed on Nasdaq First North Growth Market Stockholm (ticker: GUARD).

Certified Adviser is Redeye Nordic Growth AB, Certified Adviser - Redeye.

Attachments

Guard Therapeutics Receives Conditional Approval for Continued Listing on Nasdaq First North Growth Market and Publishes Company Description

Öppna PDF

Fler nyheter från Guard Therapeutics

Relaterade pressmeddelanden och bolagshändelser från samma bolag.

Se bolagssidan